Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

TScan Therapeutics Inc

TCRX ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$0.33

▲ +3.02%

Market Cap $22.43M · Vol 131.90K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$22.43M

Micro Cap

Div Yield

N/A

EPS Growth

+19.45%

YoY

RSI (14)

9.31

Momentum

Beta

1.12

vs Market

52W High

$2.56

87.07% below

52W Low

$0.29

12.78% above

Volume

131.90K

Avg 77.26K

P/B

0.46

Price-to-book

ROE

-71.28%

Return on equity

Free Float

99.81%

Public shares

Shariah Compliance8 STANDARDS

✗ TScan Therapeutics Inc (TCRX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TCRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.27%

-57.50%

-60.97%

-68.77%

YTD

-66.90%

-80.76%

-88.55%

-95.08%

Financials & Valuation

TTM · Annual

Total Revenue	$10.33M
Net Income	$-129,766,000.00
Revenue Growth (YoY)	-65.83%
Gross Margin	100.00%
Operating Margin	-1,296.01%
Net Profit Margin	-1,256.81%
ROE	-71.28%
ROA · ROIC	-43.26% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	12.57
P/B	0.46
P/FCF	N/A
EPS Growth	+19.45%
Outstanding Shares	67.78M

Technical Indicators

50-Day SMA	$0.73
200-Day SMA	$0.98
RSI (14)	9.31
Beta	1.12
52-Week High	$2.56
52-Week Low	$0.29

Volume Today	131.90K
Avg Daily Volume (30D)	77.26K
Relative Volume	1.71x
Volatility (10D)	269.97
Volatility (30D)	171.01
Free Float	99.81%

Analyst Consensus

HOLD

Current Price $0.33

Mean Target $2.67

52W Low$0.29 52W High$2.56

Current

Target

$0.29 $2.56

Current Analyst target

+705.64% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00PH1N025

ISINUS89854M1018

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +0.57% ARGX.BR argenx SE -1.19% ARGX argenx SE +0.50% INSM Insmed Incorporated +2.22% 2269.HK WuXi Biologics (Cayman) Inc. +1.46%

Company Profile

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is advancing two therapeutics candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells. In addition, the Company is seeking partnerships for its hematologic malignancies and autoimmune programs. Its construct consists of two proprietary components: dual-targeting antibodies that direct the virus to cytotoxic and helper T-cells and mediate T cell activation, and a non-targeting fusogen that mediates entry exclusively to T-cells. Its hematology program is designed to address patients who are diagnosed with hematologic malignancies and can benefit from undergoing allogeneic transplantation. Its TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45.